Scynexis developed its investigational fungal compound, SCY-247, which is in phase 1 clinical trials, and the company expects to share top-line data this year.
David Angulo, MD
Advertisement
Angulo is CEO of Scynexis.
Articles by David Angulo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up
2
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
3
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
4
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
5
